Remove FDA Remove Leads Remove Physicians Remove Side effects
article thumbnail

The debate on DTC marketing is going to heat up again

World of DTC Marketing

DTC ads do NOT lead to unnecessary Rxs. The FDA needs to study what people do when they see a DTC ad. They research the drug online and ask their physician about it if they decide it’s a treatment option. ” Patients want to understand how the drug works and the potential side effects before starting therapy.

Marketing 285
article thumbnail

FDA accepts Ardelyx’s NDA resubmission for XPHOZAH

Pharma Leaders

The US Food and Drug Administration (FDA) has accepted Ardelyx’s resubmitted New Drug Application (NDA) for XPHOZAH (tenapanor) to control serum phosphate in adult patients with chronic kidney disease on dialysis who have had an insufficient response or intolerance to a phosphate binder therapy.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

A realistic view of healthcare in 2022

World of DTC Marketing

1ne: The value proposition of prescription drugs still outweighs potential side effects – Wegovy’s demand quickly exceeded supply after the FDA approved once-weekly semaglutide injections. Here are things I believe are more realistic. I expect more companies to integrate more health monitors into wearable devices.

article thumbnail

EndoStim Receives FDA Breakthrough Device Designation for the EndoStim System for the Treatment of Drug Refractory GERD

Legacy MEDSearch

Food and Drug Administration (FDA) granted Breakthrough Device Designation for the Company’s EndoStim System. “We are pleased that the FDA has recognized the therapeutic potential of the EndoStim System as a new treatment in development for drug refractory GERD,” said Eric Goorno, Chief Executive Officer of EndoStim. .

article thumbnail

Why DTC isn’t, and is, marketing

World of DTC Marketing

CPG marketers are trying to maintain market share amid price increases and smaller product sizes, leading to a more significant jump in consumerism. While there is a segment that sees the drug as a “quick fix” to lose weight, others are skeptical and want to know more about side effects and costs.

Marketing 252
article thumbnail

FDA makes moves to advance ALS research ahead of upcoming Amylyx AdCom

Pharmaceutical Technology

In the lead-up to a critical meeting that will influence the approval of a new drug for amyotrophic lateral sclerosis (ALS), the US Food and Drug Administration (FDA) has detailed its plans to advance rare neurodegenerative disease research. The FDA’s action plan. The first AdCom was critical of the study’s robustness.

FDA 98
article thumbnail

Candela Medical Receives FDA Clearance for Vbeam 595 nm Pulsed Dye Laser, a Treatment for Port Wine Stains and Hemangiomas in Pediatric Cases

Legacy MEDSearch

1 Early treatment of PWS during childhood leads to the best clinical response. 1 Early treatment of PWS during childhood leads to the best clinical response. 3,6 It stops hemangioma growth, reduces the lesion, and accelerates hemangioma regression, especially in the superficial IH, without serious side effects.

Medical 52